Q-omics provides the consensus-scored N4BP2 profile across patient tissues and cancer cell-line models. N4BP2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, N4BP2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, N4BP2 protein abundance shows 29,609 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, THCA, and LUAD as cancer lineages where N4BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for N4BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes N4BP2 survival associations across molecular data types. N4BP2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible N4BP2 RNA expression–survival associations across cancer types. High N4BP2 expression shows unfavorable associations in ACC and KICH, but favorable associations in UCS, HNSC, KIRC and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for N4BP2 RNA expression.
This table summarizes N4BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for N4BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. N4BP2 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRP, LUAD, HNSC and LUSC. The THCA box plot shows higher N4BP2 RNA expression in normal versus tumor tissue (log2 FC = −1.304, t-test p < 0.001).
This table shows molecular features associated with N4BP2 in patient tissues and cancer cell lines. In patient samples, N4BP2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, N4BP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
